Company
Synchron
Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery.
- Founded
- 2016
- HQ
- New York, NY, USA
- Funding
- $200.0M
- Models
- 1
Verified profile
1
Sources on record
0
Tracked changes
Updated recently
Last verified change
Overview
Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
DEPLOY Intelligence
Market intelligence for physical AI
Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.
Models (1)
View all models →Current leadership (1)
- Tom Oxley Founder & CEOreported, not verified
Founders (1)
- Tom Oxleycofounder
Safety record
No incidents on record for Synchron.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
Synchron in third-party press
Peer companies
- Xiaomi3 models
- Baidu2 models
- Brilliant Labs2 models
- Open Bionics2 models
- Plaud AI2 models
- Based Hardware1 model
Financial state
- Reporting basis
- private_reported
- Lifecycle stage
- growth
- Counterparty risk class
- moderate
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Funding rounds (1)
- Series D2024-12-01
$200M(reported)
Sources (1)
Common questions
- What is Synchron?
- Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.
- Where is Synchron based?
- Synchron is based in New York, NY, USA.
- When was Synchron founded?
- Synchron was founded in 2016.
- What does Synchron make?
- Synchron has 1 robot model on the DEPLOY registry: Synchron Stentrode (Synchron builds physical robots).
- Where does Synchron operate robots?
- Synchron is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is Synchron safe?
- Synchron has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 1 source (no primary) · last reviewed 2026-07-06
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-06
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Synchron.Peer companies
- Xiaomi3 models
- Baidu2 models
- Brilliant Labs2 models
- Open Bionics2 models
- Plaud AI2 models
- Based Hardware1 model
In the press
Recent coverage mentioning Synchron from third-party publications. Automatically surfaced; not part of the verified registry record.
Brain-computer interface based on Rice research wins FDA approval for first clinical trial
A brain-computer interface based on Rice University research won FDA approval for its first clinical trial, advancing BCI technology for patients with paralysis or amputation.
Synchron raises $200M Series D to support BCI commercialization
Synchron raised $200M in Series D financing to support commercialization of its Stentrode brain-computer interface, bringing total funding to over $345M and pushing BCI investment…
Synchron's Brain-Computer Interface Evaluated in COMMAND Early Feasibility Study
Synchron's COMMAND study showed reliable performance of the Stentrode BCI implant with no serious adverse events related to the brain or vasculature during the 12-month period…
Machine-readable surfaces
- Markdown mirror: /companies/synchron.md
- RSS feed: /companies/synchron/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/ac5afad9-cfd5-4b66-aa18-4d3aacf16560
- Revision history: /companies/synchron/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Xiaomi3 models
- Baidu2 models
- Brilliant Labs2 models
- Open Bionics2 models
- Plaud AI2 models
- Based Hardware1 model